GlobeNewswire

Arbitrade Appoints Three New Independent Directors to Its Board

Dela

Makes two key senior management appointments - a new Chief Financial Officer and Senior Vice President of Technology and President of its subsidiary, ArbiPay

NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Mr. Leonard Schutzman, Chairman and Chief Executive of Arbitrade, a leading coin/cryptocurrency exchange, has announced the appointment of three new independent directors to Arbitrade's board together with two key executive appointments.

Mr. Brent M. Longnecker will serve as Chairman of the Compensation Committee.  Mr. Longnecker has more than 30 years experience in consulting for public and private organizations and has built one of the country's leading, privately held executive management consultancies, serving both domestic and international markets. Mr. Longnecker serves on the board of the National Association of Corporate Directors (NACD).

Mr. Bob DeRodes has over 45 years of experience in information technology, focused primarily in four industry sectors - banking, airlines, payments and retail.  He has spent 15 years automating regional banks and was President of Sabre Development Services and CEO of Delta Technologies. He was also  CTO, Citibank Global Cards and Executive Vice President of First Data Global Operations & Technology.  He served as Executive Vice President and CIO of Target Brands, Inc. Mr. DeRodes has significant experience in cyber security and has been an adviser to the CIO of Homeland Security.

Mr. William Transier has also been appointed to Arbitrade's Board of Directors. He is Chief Executive Officer of Transier Advisors, LLC, an independent advisory firm providing services to companies facing stressed operational situations, turnaround, restructuring or in need of interim executive leadership. He was co-founder of Endeavour International Corporation, and international oil and gas exploration and production company. He also served as Chairman, Chief Executive Officer and President of Endeavour from September 2006 until December 2014 and then as non-executive Chairman until his retirement in November 2015. He was Executive Vice President and Chief Financial Officer of Ocean Energy, Inc., from March 1999 until April 2003 and served in various roles including KPMG, LLP, including that of partner in the audit department and head of its Global Energy practice, from June 1986 to April 1996. Mr. Transier is Chairman of the Board of Helix Energy Solutions Group, Inc.  He has been a member of its board since September 2000 and currently serves as lead Director on the Board of Directors of two non-public companies were he is the lead independent director.

Mr. Schutzman was also pleased to announce two key senior management appointments for Arbitrade and ArbiPay, Arbitrade's banking system subsidiary. 

Mr. Larry Meyer has been appointed Executive Vice President and Chief Financial Officer of Arbitrade. He brings a wealth of financial management experience to the company, having served in numerous positions during a decade with PepsiCo including Regional Finance Director for Pepsi Cola International where he expanded the company and restructured operations.  During the decade of the 1990's, while both companies were public, he was Chief Financial Officer at Toys R Us International where he expanded the business and he was CFO of Gymboree where he turned around the company.  From 2001 to 2012, he was Executive Vice President  and CFO of Forever 21 during which time the business few from a regional chain to a global brand.  He was most recently Chief Executive Officer of Unniqlo's U.S. business. Mr. Schutzman said, "Larry's brilliance as a strategic thinker, combined with his deal making ability and formidable international experience, makes him a perfect addition to Arbitrade's executive leadership team."

Mr. Mohammad Markatia, already a Director of Arbitrade, has joined the company's management team and will serve as Arbitrade's Senior Vice President of Technology.  He will also serve both as President and President of Technology at ArbiPay, Arbitrade's payment systems subsidiary company.

In announcing these key appointments, Mr. Schutzman said,"Arbitrade and our subsidiary company, ArbiPay, are fortunate to have the services of these 5 talented executives.  They add strength to a Board of Directors and senior management team that provides experience and capabilities which are unrivaled in the fast growing and dynamic cypto currency and payments industry."

ARBITRADE, through its proprietary software and strategic partnerships, plans to be in all segments of the cryptocurrency business, including currency mining, trading (The ARBITRADE Exchange) gift cards, debit cards, money transfer and Point of Sale processing.

Media Contact: 
Victor Webb 
Marston Webb International 
T: (212) 684-6601, C: (917) 887-0418 
e-mail: marwebint@cs.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Arbitrade via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum